Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07263594 · ClinicalTrials.gov registry record · Phase 1
A Study of DB-1324 in Advanced/Metastatic Gastrointestinal Tumors
A Phase 1 study, sponsored by DualityBio.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 127
- Enrollment target
NCT07263594 is a Phase 1 study that is actively recruiting participants, run by DualityBio. The registered enrollment target is 127 participants.
The verdict
NCT07263594, a Phase 1 study, is actively recruiting participants, sponsored by DualityBio.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 127 participants
- Enrollment target
Study Summary
This study, the first clinical trial, aims to determine the safety, tolerability, pharmacokinetics, pharmacodynamics, maximum tolerated dose, and antitumor activity of DB-1324.
Interventions
- DRUG DB-1324
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 127 participants |
| Start Date | 2026-01-20 |
| Est. Completion | 2028-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07263594
The ClinicalTrials.gov registry entry for NCT07263594 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 127 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is DualityBio, which has 10 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which DB-1324 is the first listed.
NCT07263594 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07263594 about?
NCT07263594 is a clinical study titled "A Study of DB-1324 in Advanced/Metastatic Gastrointestinal Tumors". This study, the first clinical trial, aims to determine the safety, tolerability, pharmacokinetics, pharmacodynamics, maximum tolerated dose, and antitumor activity of DB-1324.
What is the current status of trial NCT07263594?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 127 participants. The study started on 2026-01-20. Estimated completion is 2028-12.
What interventions are being tested in trial NCT07263594?
The interventions under investigation include: DB-1324 (DRUG).
Who is sponsoring clinical trial NCT07263594?
This trial is sponsored by DualityBio, which has 10 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.